1. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. Issue 3 (September 2022) Authors: Su, Bin; Yao, Cheng; Zhao, Qing-Xia; Cai, Wei-Ping; Wang, Min; Lu, Hong-Zhou; Mu, Ting-Ting; Chen, Yuan-Yuan; Liu, Li; Wang, Hui; He, Yun; Zheng, Yu-Huang; Li, Ling-Hua; Chen, Jin-Feng; Yu, Jian-Hua; Zhu, Biao; Zhao, Min; Sun, Yong-Tao; Lun, Wen-Hui; Zhang, Yi-Hang Journal: Journal of infection Issue: Volume 85:Issue 3(2022) Page Start: 334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗